TIDMORPH

RNS Number : 4688M

Open Orphan PLC

24 May 2022

Open Orphan plc

("Open Orphan" or the "Company")

Notice of results

Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials , announces that it will release its full year results for the year ended 31 December 2021 on Tuesday 7 June 2022.

Investor Presentation

Yamin 'Mo' Khan, Chief Executive Officer, and Leo Toole, Chief Financial Officer, will be hosting a live online presentation relating to the final results via the Investor Meet Company platform at 6pm on Tuesday 7 June 2022. The presentation is open to all existing and potential shareholders.

Investors can sign up to Investor Meet Company for free and register for the presentation here.

Investors who already follow Open Orphan on the Investor Meet Company platform will automatically be invited.

Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the "Ask a Question" function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation and a PDF of the slides used will be available on the Investor Meet Company platform and the Company's website afterwards.

For further information please contact:

 
Open Orphan plc                                                      +44 (0) 20 7756 1300 
Yamin Khan, Chief Executive Officer 
 
Liberum Capital (Nominated Adviser 
 and Joint Broker)                                                   +44 (0) 20 3100 2000 
Ben Cryer/ Edward Mansfield/ Phil 
 Walker/ Will King 
 
finnCap plc (Joint Broker)                                           +44 (0) 20 7220 0500 
Geoff Nash / James Thompson / Richard 
 Chambers 
 
Davy (Euronext Growth Adviser and 
 Joint Broker)                                                        +353 (0) 1 679 6363 
Anthony Farrell 
 
Walbrook PR (Financial PR & IR)          +44 (0)20 7933 8780 or openorphan@walbrookpr.com 
 Paul McManus / Sam Allen /                        +44 (0)7980 541 893 / +44 (0) 7502 558 
 Louis Ashe-Jepson                                                                  258 / 
                                                                      +44 (0) 7747 515393 
 
 

Notes to Editors

Open Orphan plc (London and Euronext: ORPH) is a rapidly growing contract research company that is a world leader in testing infectious and respiratory disease products using human challenge clinical trials. The Company provides services to Big Pharma, biotech, and government/public health organisations.

The Company has a leading portfolio of human challenge study models for infectious and respiratory diseases and is developing a number of new models, such as malaria and COVID-19, to address the dramatic growth of the global infectious disease market. The Paris and Breda offices have over 25 years of experience providing drug development services such as biometry, data management, statistics CMC, PK and medical writing to third party clients as well as supporting the London-based challenge studies.

Open Orphan runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its newly opened clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester. The newly opened facilities have expanded the scope of the business to enable the offering of Phase I and Phase II vaccine field trials, PK studies, bridging studies, and patient trials as part of large international multi-centre studies.

Building upon its many years of challenge studies and virology research, the Company is developing an in-depth database of infectious disease progression data. Based on the Company's Disease in Motion(R) platform, this unique dataset includes clinical, immunological, virological, and digital (wearable) biomarkers.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORSEMFEDEESEEI

(END) Dow Jones Newswires

May 24, 2022 03:09 ET (07:09 GMT)

Open Orphan (LSE:ORPH)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Open Orphan Charts.
Open Orphan (LSE:ORPH)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Open Orphan Charts.